Authors

Latest:

Rapid Readout: HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB Transplantation

Expert hematologist/oncologist Paul Szabolcs, MD, reviews positive data from a clinical trial comparing hematopoietic stem cell transplantation and omidubicel with standard cord blood transplantation.

Allina Health

Latest:

Allina Health Cancer Institute Begins First-of-its-Kind Clinical Trial to Revolutionize Cancer Treatment and Diagnosis

Allina Health Cancer Institute is collaborating with St. Paul-based Astrin Biosciences for a first-of-its-kind clinical trial using artificial intelligence and a simple blood draw to revolutionize how cancer is diagnosed and treated.

Marcel van den Brink, MD, PhD

Latest:

Dr van den Brink on a High-Fiber Dietary Intervention in Smoldering Multiple Myeloma

Marcel van den Brink, MD, PhD, discusses a high-fiber dietary intervention for early-stage plasma cell disorders designed for multiple myeloma

University of California Health

Latest:

University of California Lung Cancer Consortium and AstraZeneca Expand Healthy Lungs California Initiative to Improve Early Lung Cancer Detection and Screening Statewide

The University of California Lung Cancer Consortium and AstraZeneca announced a five-year partnership to expand the Healthy Lungs California initiative.

Warren Fingrut, MD

Latest:

Dr. Fingrut on the Association Between Ancestry, Socioeconomic Status, and HLA-Disparate Grafts

Warren Fingrut, MD, discusses the association between non-European ancestry and low socioeconomic status with the receipt of HLA-disparate grafts.

Aileen I. Fernandez, PhD

Latest:

Dr. Fernandez on the Utility of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

Aileen I. Fernandez, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Prakash Pandalai, MD

Latest:

Dr. Pandalai on Outcomes With Adjuvant HIPEC in CRC

Prakash Pandalai, MD, discusses outcomes with adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer.

Marty Trieschmann

Latest:

UAMS Breast Cancer Program Earns National Reaccreditation

The Breast Cancer program at the University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute has earned reaccreditation from the National Accreditation Program for Breast Centers.

Karen L. Klugo, MD

Latest:

BCMA-Targeting Therapies for RRMM: Future Perspectives

Considerations for optimizing treatment with BCMA-targeting agents for patients with relapsed/refractory multiple myeloma moving forward.

Katharina Hoebel, MD, PhD

Latest:

Dr Hoebel on Modeling Spatial Interactions to Predict Outcomes in NSCLC

Katharina Hoebel, MD, PhD discusses the efficacy of incorporating spatial interactions within predictive models, in the realm of oncology.

Bhagirathbhai Dholaria, MBBS

Bhagirathbhai Dholaria, MBBS, is an associate professor of medicine in the Division of Hematology Oncology at Vanderbilt University Medical Center.

Latest:

Dr Dholaria on Future Research Directions With P-BCMA-ALLO1 in R/R Multiple Myeloma

Bhagirathbhai Dholaria, MBBS, discusses future directions for research with P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma.

Phyu Aung, MD, PhD, FCAP

Latest:

Advances in Diagnosis and Targeted Therapies for BPDCN from an Expert Dermatopathologist

Phyu Aung, MD, PhD, FCAP, a dermatopathologist, discusses key challenges in diagnosing and treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Definitive diagnosis is difficult given BPDCN’s heterogeneous features and frequent skin and CNS involvement. Recent advances have utilized immunophenotyping and targeted CD123, which is overexpressed on BPDCN cells. However, resistance develops with CD123 monotherapy. She notes that while testing aids BPDCN insights, more prognostic markers are needed, and emphasizes that continued cross-disciplinary research is critical to better outcomes.

Yonina R. Murciano-Goroff, MD, MSc, DPhil

Latest:

Dr Murciano-Goroff on the Evaluation of LY3537982 in KRAS G12C–Mutated NSCLC, CRC and Other Solid Tumors

Yonina R. Murciano-Goroff, MD, MSc, DPhil, discusses the evaluation of LY3537982 in patients with KRAS G12C–mutated non–small cell lung cancer, colorectal cancer, and other solid tumors.

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Latest:

Gifts from Walther, Regenstrief Foundations Create Cancer Informatics Chair at IU Simon Comprehensive Cancer Center

Gifts totaling $3 million will create an endowed chair in cancer informatics at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Denis M. Gilmore, MD

Sunandana Chandra, MD, Northwestern Medicine

Latest:

Advances in the Treatment of Malignant Melanoma

Skyler B. Johnson, MD

Latest:

Fellows Can Join the Fight Against Cancer Misinformation Online

Many cancer organizations across the United States and internationally acknowledge a need for in-novative uses of social technology to improve cancer-related support and information provision.

Jiahn Choi, PhD

Latest:

The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality

One of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.

Nathan Bahary, MD, PhD

Latest:

Dr. Bahary on the Benefits of Ivosidenib in IDH1-Mutated Cholangiocarcinoma

Nathan Bahary, MD, PhD, discusses the benefits of ivosidenib in patients with intrahepatic cholangiocarcinoma whose tumors harbor IDH1 mutations.

Kimberly Cannavale, MPH

Latest:

Cannavale on the Importance of Assessing Comorbidities and Remission Rates in Ovarian Cancer

Kimberly Cannavale, MPH, discusses the clinical implications of a study on the impact of pre-existing comorbidities on remission rates in ovarian cancer.